Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19

Jane A. O’Halloran, Eyal Kedar, Kevin J. Anstrom, Matthew W. McCarthy, Emily R. Ko, Patricia Segura Nunez, Cynthia Boucher, P. Brian Smith, Reynold A. Panettieri Jr, Sabina Mendivil Tuchia de Tai, Martin Maillo, Akram Khan, Alfredo J. Mena Lora, Matthias Salathe, Gerardo Capo, Daniel Rodríguez Gonzalez, Thomas F Patterson, Christopher Palma, Horacio Ariza, Maria Patelli Lima, Anne M. Lachiewicz, John Blamoun, Esteban C. Nannini, Eduardo Sprinz, Analia Mykietiuk, Radica Alicic, Adriana M. Rauseo, Cameron R. Wolfe, Britta Witting, Daniel K. Benjamin Jr, Steven E. McNulty, Pearl Zakroysky, Susan Halabi, Sandra Butler, Jane Atkinson, Stacey J. Adam, Richard Melsheimer, Soju Chang, Lisa LaVange, Michael Proschan, Samuel A. Bozzette, William G. Powderly, ACTIV-1 IM study group members
doi: https://doi.org/10.1101/2022.09.22.22280245

Article Information

doi 
https://doi.org/10.1101/2022.09.22.22280245
History 
  • September 26, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Jane A. O’Halloran, MD, PhD1,
  2. Eyal Kedar, MD4,
  3. Kevin J. Anstrom, PhD3,
  4. Matthew W. McCarthy, MD2,
  5. Emily R. Ko, MD, PhD5,
  6. Patricia Segura Nunez, MD6,
  7. Cynthia Boucher, MS7,
  8. P. Brian Smith, MD, MPH, MHS8,
  9. Reynold A. Panettieri Jr, MD9,
  10. Sabina Mendivil Tuchia de Tai, MD10,
  11. Martin Maillo, MD11,
  12. Akram Khan, MD12,
  13. Alfredo J. Mena Lora, MD13,
  14. Matthias Salathe, MD14,
  15. Gerardo Capo, MD15,
  16. Daniel Rodríguez Gonzalez, MD16,
  17. Thomas F Patterson, MD17,
  18. Christopher Palma, MD, ScM18,
  19. Horacio Ariza, MD19,
  20. Maria Patelli Lima, MD20,
  21. Anne M. Lachiewicz, MD3,13,
  22. John Blamoun, MD21,
  23. Esteban C. Nannini, MD22,
  24. Eduardo Sprinz, MD23,
  25. Analia Mykietiuk, MD24,
  26. Radica Alicic25,
  27. Adriana M. Rauseo, MD1,
  28. Cameron R. Wolfe, MBBS, MPH5,
  29. Britta Witting2,
  30. Daniel K. Benjamin Jr, MD, MPH, PhD8,
  31. Steven E. McNulty, MS8,
  32. Pearl Zakroysky8,
  33. Susan Halabi, PhD8,
  34. Sandra Butler, PhD26,
  35. Jane Atkinson, DDS7,
  36. Stacey J. Adam, PhD27,
  37. Richard Melsheimer28,
  38. Soju Chang, MD, MPH7,
  39. Lisa LaVange, PhD3,
  40. Michael Proschan, PhD29,
  41. Samuel A. Bozzette, MD, PhD7,
  42. William G. Powderly, MD1,*,
  43. ACTIV-1 IM study group members
  1. 1Washington University St. Louis, St Louis, MO
  2. 2Weill Cornell Medicine in New York
  3. 3University of North Carolina, Chapel Hill, NC
  4. 4St. Lawrence Health, Potsdam, NY
  5. 5Duke University Medical Center, Durham, NC
  6. 6Hospital Nacional Hipolito Unanue, Lima, Peru
  7. 7National Center for Advancing Translational Sciences
  8. 8Duke Clinical Research Institute (DCRI)
  9. 9Robert Wood Johnson Medical School, New Brunswick, NJ
  10. 10Hospital Central de la Fuerza Aerea del Peru, Lima, Peru
  11. 11Sanatorio Diagnostico, Santa Fe, Argentina
  12. 12Oregon Health and Science University, Portland, OR
  13. 13University of Illinois at Chicago, Chicago, IL
  14. 14University of Kansas Medical Center, Kansas City, KS
  15. 15Trinitas Hospital, Elizabeth, NY
  16. 16Nuevo Hospital Civil de Guadalajara Juan I. Menchaca, Guadalajara, Mexico
  17. 17University of Texas Health Science Center at San Antonio, San Antonio, TX
  18. 18University of Rochester School of Medicine and Dentistry, Rochester, NY
  19. 19Clinica Central S.A., Villa Regina, Argentina
  20. 20Hospital e Maternidade Celso Pierro - PUC Campinas, Campinas, Brazil
  21. 21MidMichigan Medical Center – Midland, Midland, MI
  22. 22Sanatorio Britanico. Santa Fe, Argentina
  23. 23Hospital de Clinicas de Porto Alegre HCPA, Porto Alegre, Brazil
  24. 24Instituto Medico Platense, La Plata, Argentina
  25. 25Providence Medical Research Center, Spokane, WA
  26. 26Technical Resources International (TRI), Bethesda MD
  27. 27Foundation for the National Institutes of Health (FNIH)
  28. 28Janssen Pharmaceuticals
  29. 29National Institute of Allergy and Infectious Diseases (NIAID)
  1. ↵*Address for correspondence:
    William G. Powderly, MD, Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110. Email: Wpowderly{at}wustl.edu.
Back to top
Posted September 26, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19
Jane A. O’Halloran, Eyal Kedar, Kevin J. Anstrom, Matthew W. McCarthy, Emily R. Ko, Patricia Segura Nunez, Cynthia Boucher, P. Brian Smith, Reynold A. Panettieri Jr, Sabina Mendivil Tuchia de Tai, Martin Maillo, Akram Khan, Alfredo J. Mena Lora, Matthias Salathe, Gerardo Capo, Daniel Rodríguez Gonzalez, Thomas F Patterson, Christopher Palma, Horacio Ariza, Maria Patelli Lima, Anne M. Lachiewicz, John Blamoun, Esteban C. Nannini, Eduardo Sprinz, Analia Mykietiuk, Radica Alicic, Adriana M. Rauseo, Cameron R. Wolfe, Britta Witting, Daniel K. Benjamin Jr, Steven E. McNulty, Pearl Zakroysky, Susan Halabi, Sandra Butler, Jane Atkinson, Stacey J. Adam, Richard Melsheimer, Soju Chang, Lisa LaVange, Michael Proschan, Samuel A. Bozzette, William G. Powderly, ACTIV-1 IM study group members
medRxiv 2022.09.22.22280245; doi: https://doi.org/10.1101/2022.09.22.22280245
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area